Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of belimumab with rituximab/venetoclax in relapsed or refractory CLL
2020-002622-87Phase 2Active
- Sponsor
- University Hospital Tübingen
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of belimumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by University Hospital Tübingen. Primary endpoint: Negativity rate of minimal residual disease in peripheral blood. Started Jun 2021; status: active.
02
Drugs
belimumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2020-002622-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002622-87.